Rise Baking Company Appoints Sarah Testa as Chief Commercial Officer
Testa brings extensive knowledge and experience in the consumer-packaged goods food industry, with a strong track record in enterprise growth strategy and commercial transformation. She has held executive leadership roles at Flagstone Foods and TreeHouse Foods, and most recently served as Chief Growth Officer at Roskam Foods. Earlier in her career, she held management and brand strategy roles at Deloitte, Target and ConAgra. Known for her people-centered leadership style, she has a talent for building strong teams, aligning organizations around a shared vision and delivering sustainable growth across both branded and private label platforms.
"Sarah is a proven leader with the vision and experience to help accelerate our growth and strengthen our customer partnerships," said
"I'm excited to join at such a pivotal moment for the company and be part of a team that is so clearly focused on its people, customers and future," added Testa. "I look forward to building on the company's strong foundation."
This announcement reflects Rise Baking Company's commitment to strengthening its customer partnerships as a leader in the bakery industry. It is also a testament to Rise investing in its people and building a high-performing, collaborative culture. By supporting and developing its teams, the company is creating an environment where employees can thrive and drive long-term success.
For additional information on Rise Baking Company, visit www.risebakingcompany.com.
About Rise Baking Company:
Formed in 2013, Rise Baking Company is a North American bakery manufacturer headquartered in
Headshot HERE
View original content to download multimedia:https://www.prnewswire.com/news-releases/rise-baking-company-appoints-sarah-testa-as-chief-commercial-officer-302765866.html
SOURCE Rise Baking Company
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Samsonite Group S.A. to Acquire BÉIS, Expanding its Lifestyle Portfolio and Enhancing Digital Capabilities
- Zipalertinib Plus Chemotherapy Meets Primary Endpoint of Progression-Free Survival in Planned Interim Analysis of Phase 3 REZILIENT3 Trial in First-Line EGFR Exon 20 Insertion Mutation Non-Small Cell
- Lithium Ionic Announces Agreement to Sell its Salinas Group of Lithium Properties to PLS for US$37.5 Million in Cash, Retaining a 2.0% Royalty on Future Spodumene Sales
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share